RxDoctor Payments DataLook up a doctor →

Michael Arcarese, MD

Interventional Cardiology · Richmond, VANPI 1164452363

Payments from drug & device makers

$88,420in general payments, 2019–2025

Across 523 payments — averaging $169.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$40K
  • Cleerly, Inc.$21K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Amgen$5K
  • Boston Scientific$1K
  • Novartis$959
  • plus $7K from 41 others

What the payments were for

  • Consulting fees$350%
  • Food & beverage$10,31099%
  • Education$841%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,420 in reported general payments places this provider in the 85th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$459,591
Medicare patients
1,944
Services billed
5,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$488,307
Repatha SureclickEvolocumab314$317,890
EntrestoSacubitril/Valsartan242$264,079
XareltoRivaroxaban194$211,905
JardianceEmpagliflozin165$162,105
FarxigaDapagliflozin Propanediol108$89,914
BrilintaTicagrelor72$53,130
Praluent PenAlirocumab49$26,786
VascepaIcosapent Ethyl29$17,339
EdarbyclorAzilsartan Med/Chlorthalidone26$13,497
Rosuvastatin Calcium1,029$13,191
EdarbiAzilsartan Medoxomil22$11,372
Repatha SyringeEvolocumab14$10,933
LivaloPitavastatin Calcium24$10,173
Metoprolol Succinate763$8,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$478$488,307391 claims
NovartisEntresto$959$264,079242 claims
Johnson & JohnsonXarelto$492$211,905194 claims
Boehringer IngelheimJardiance$556$162,105165 claims
AstraZenecaFarxiga, Brilinta$706$143,044180 claims
Kowa Pharmaceuticals America, Inc.Livalo$106$10,17324 claims
Esperion Therapeutics, Inc.Nexletol$90$7,54213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →